No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NRXP240719P2500
- 0.30
- 0.000.00%
15min DelayTrading Jul 9 10:10 ET
0.30High0.30Low
0.30Open0.30Pre Close1 Volume0 Open Interest2.50Strike Price30.00Turnover0.00%IV0.36%PremiumJul 19, 2024Expiry Date0.29Intrinsic Value100Multiplier10DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma7.36Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Express News | NRx Pharmaceuticals Outlines Potential Paths To Revenue And Profitability In 2025; New Shareholder Update Highlights Potential 2024 Revenue From HOPE Therapeutics-Branded Clinics, 2025 Revenue From Sales Of NRX-100 (IV Ketamine) Pending FDA Approval,...
Press Release: NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter PR Newswire RADNOR, Pa., July 1, 2024 -- Potential paths to revenue and profitability in 2025 RADNOR, Pa., July 1, 2024 /PR
Express News | NRX Pharmaceuticals Inc: Nda for NRX-100 in Advanced Preparation for Submission in 2024, Potential Revenue in 2025
Express News | NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
Express News | NRX Pharmaceuticals Inc - Agreement Provided for the Joint Development, Supply, Marketing, Commercialization and License to Alvogen of NRX-101
Express News | NRX Pharmaceuticals Inc - Continues to Finalize a New Drug Approval Application for Intravenous Ketamine (NRX-100), to Be Submitted This Year
Comments
$NRX Pharmaceuticals(NRXP.US$
loading zone
loading zone
$NRX Pharmaceuticals(NRXP.US$ Reuters· just
NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
$NRX Pharmaceuticals (NRXP.US)$ Here is why OCGN will skyrocket 400% to 800% over the next 9 to 12 months.
What is OCU400's market potential? If we take Ocugen's estimates seriously, it is mouthwatering. The biotech projects that OCU400 could earn approval in 2026. Ocugen thinks the therapy could generate between $30 billion and $47 billion in total revenue in the five years after approval. The company's market cap is about $488 million as of this writing. So by any standar...
What is OCU400's market potential? If we take Ocugen's estimates seriously, it is mouthwatering. The biotech projects that OCU400 could earn approval in 2026. Ocugen thinks the therapy could generate between $30 billion and $47 billion in total revenue in the five years after approval. The company's market cap is about $488 million as of this writing. So by any standar...
12
Read more